Study on pharmacokinetic interactions between SHR2554 and itraconazole in healthy subjects: A single‐center, open‐label phase I trial

BACKGROUND: SHR2554, a novel oral Enhancer of Zeste Homolog 2 inhibitor, shows broad‐spectrum anti‐tumor efficacy in preclinical studies. As SHR2554 is mainly metabolized by CYP3A4, it is helpful to conduct research on the effects of itraconazole, a strong inhibitor of CYP3A4‐metabolizing enzymes, o...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Kunhong, Zou, Yi, Zou, Chan, Wang, Hong, Xiang, Yuxia, Yang, Xiaoyan, Yang, Shuang, Cui, Chang, Yang, Guoping, Huang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883540/
https://www.ncbi.nlm.nih.gov/pubmed/35841331
http://dx.doi.org/10.1002/cam4.5028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883540/
https://www.ncbi.nlm.nih.gov/pubmed/35841331
http://dx.doi.org/10.1002/cam4.5028

Ejemplares similares